357 related articles for article (PubMed ID: 29579338)
1. Development of CNS metastases and survival in patients with inflammatory breast cancer.
Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
3. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
[TBL] [Abstract][Full Text] [Related]
4. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
7. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
Tsai CJ; Li J; Gonzalez-Angulo AM; Allen PK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Yang W; Cristofanilli M; Valero V; Buchholz TA
Am J Clin Oncol; 2015 Jun; 38(3):242-7. PubMed ID: 23648437
[TBL] [Abstract][Full Text] [Related]
8. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.
Kupstas AR; Hoskin TL; Day CN; Boughey JC; Habermann EB; Hieken TJ
Br J Surg; 2020 Jul; 107(8):1033-1041. PubMed ID: 32057107
[TBL] [Abstract][Full Text] [Related]
9. Modern outcomes of inflammatory breast cancer.
Rehman S; Reddy CA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
[TBL] [Abstract][Full Text] [Related]
10. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
11. Incidence of and survival following brain metastases among women with inflammatory breast cancer.
Dawood S; Ueno NT; Valero V; Andreopoulou E; Hsu L; Lara J; Woodward W; Buchholz TA; Hortobagyi GN; Cristofanilli M
Ann Oncol; 2010 Dec; 21(12):2348-2355. PubMed ID: 20439340
[TBL] [Abstract][Full Text] [Related]
12. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
[TBL] [Abstract][Full Text] [Related]
13. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory breast cancer appearance at presentation is associated with overall survival.
Balema W; Liu D; Shen Y; El-Zein R; Debeb BG; Kai M; Overmoyer B; Miller KD; Le-Petross HT; Ueno NT; Woodward WA
Cancer Med; 2021 Sep; 10(18):6261-6272. PubMed ID: 34327874
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
16. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
19. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction.
Raghav K; French JT; Ueno NT; Lei X; Krishnamurthy S; Reuben JM; Valero V; Ibrahim NK
PLoS One; 2016; 11(1):e0145534. PubMed ID: 26752563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
